Crown Bioscience realigns its leadership team

Crown Bioscience, a subsidiary of Crown Bioscience International and a worldwide global drug discovery and development services company that provides translational platforms that improve the research of oncology and metabolic diseases, has named Dr. Jean Pierre Wery its CEO.
"In 2016, CrownBio has experienced unprecedented growth with increasing demand for our Immuno-Oncology and Cardiovascular and Metabolic Disease services and models," Wery said. "As newly appointed CEO, my objective is to foster the development of new products, cutting-edge technologies, and services for oncology and metabolic disease, while contemplating a possible expansion into new therapeutic areas."
Taking the mantle of president and chief strategy officer will be Dr. Alex Wu, co-founder of CrownBio. Eva Ho will serve as the company’s chief financial officer, bringing experience in financial planning and analysis to her new role. She will take the role from Bing Zhu, who will now serve as chief operating officer.
"I am pleased Ms. Ho has joined CrownBio and I am looking forward to leading the next phase of the company's strategic initiatives," Wu said.